Results 241 to 250 of about 298,867 (391)
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley +1 more source
Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood: A Case Series. [PDF]
Zarrabi M +5 more
europepmc +1 more source
What's New? The understanding of the epidemiological and clinical distinctions between Epstein–Barr virus (EBV)‐positive and EBV‐negative classic Hodgkin lymphoma remains incomplete. Here, the authors generated unique sets of population‐based sex‐ and age‐specific incidence rates of classic Hodgkin lymphoma in Denmark stratified by histological subtype
Klaus Rostgaard +18 more
wiley +1 more source
A Case of Epstein-Barr Virus-Associated Transplanted Kidney Post-Transplant Lymphoproliferative Disorder Complicated by Hemophagocytic Lymphohistiocytosis, Six Years after Transplantation. [PDF]
Waseda T, Aida N, Ito T, Kenmochi T.
europepmc +1 more source
Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci +5 more
wiley +1 more source
Manufacturing and clinical applications of non‐CAR‐T immune effector cells
Transfusion, EarlyView.
Thane Kubik +2 more
wiley +1 more source
Acute genital ulceration in a 14-month-old girl with <i>rhinovirus</i> infection and new onset B-cell acute lymphoblastic leukemia. [PDF]
Andre M, Purvis C, Motaparthi K.
europepmc +1 more source

